{"clinical_study": {"@rank": "47", "required_header": {"download_date": "ClinicalTrials.gov processed this data on April 06, 2020", "link_text": "Link to the current ClinicalTrials.gov record.", "url": "https://clinicaltrials.gov/show/NCT04331834"}, "id_info": {"org_study_id": "PrEP_COVID", "nct_id": "NCT04331834"}, "brief_title": "Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic", "acronym": "PrEP_COVID", "official_title": "Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Unicentric, Double-Blinded Randomized Controlled Trial", "sponsors": {"lead_sponsor": {"agency": "Barcelona Institute for Global Health", "agency_class": "Other"}, "collaborator": [{"agency": "Hospital Clinic of Barcelona", "agency_class": "Other"}, {"agency": "Laboratorios Rubi\u00f3", "agency_class": "Other"}]}, "source": "Barcelona Institute for Global Health", "oversight_info": {"is_fda_regulated_drug": "No", "is_fda_regulated_device": "No", "is_us_export": "No"}, "brief_summary": {"textblock": "The investigators aim to evaluate the efficacy of pre-exposure prophylaxis with\n      hydroxychloroquine in healthcare workers with high-risk of SARS-CoV-2 infection."}, "overall_status": "Not yet recruiting", "start_date": {"@type": "Anticipated", "#text": "April 3, 2020"}, "completion_date": {"@type": "Anticipated", "#text": "October 30, 2020"}, "primary_completion_date": {"@type": "Anticipated", "#text": "October 3, 2020"}, "phase": "Phase 3", "study_type": "Interventional", "has_expanded_access": "No", "study_design_info": {"allocation": "Randomized", "intervention_model": "Parallel Assignment", "primary_purpose": "Prevention", "masking": "Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)"}, "primary_outcome": {"measure": "Confirmed cases of a COVID-19", "time_frame": "Up to 6 months after start of treatment", "description": "Confirmed cases of a COVID-19 (defined by symptoms compatible with COVID-19 and/or a positive PCR for SARS-CoV-2) in the PrEP group compared to the placebo group at any time during the 6 months of the follow-up in healthcare workers with negative PCR for SARS-CoV-2 at day 0."}, "secondary_outcome": [{"measure": "SARS-CoV-2 seroconversion", "time_frame": "Up to 6 months after start of treatment", "description": "SARS-CoV-2 seroconversion in the PrEP group compared to placebo in during 6 months of follow-up in healthcare workers with negative serology at day 0."}, {"measure": "Occurrence of any adverse event related with hydroxychloroquine treatment", "time_frame": "Up to 6 months after start of treatment", "description": "Incidence of clinical and/or laboratory adverse events will be compared in the PrEP group and in the placebo arm."}, {"measure": "Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers", "time_frame": "Up to 6 months after start of treatment", "description": "Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers will be estimated by the number of healthcare workers diagnosed with COVID-19 in the placebo group, among the total of healthcare workers included in the non-PrEP group during the study period."}, {"measure": "Risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19", "time_frame": "Up to 6 months after start of treatment"}, {"measure": "COVID-19 Biobank", "time_frame": "Up to 6 months after start of treatment", "description": "A repository (biobank) of serum samples obtained from healthcare workers confirmed COVID-19 cases for future research on blood markers to predict SARS-CoV-2 infection."}], "number_of_arms": "2", "enrollment": {"@type": "Anticipated", "#text": "440"}, "condition": "COVID-19", "arm_group": [{"arm_group_label": "Pre-exposure prophylaxis of SARS-CoV-2", "arm_group_type": "Experimental", "description": "Participants will receive hydroxychloroquine 400 mg daily during the first 4 days, followed by 400 mg weekly during 6 months"}, {"arm_group_label": "Control group with placebo", "arm_group_type": "Placebo Comparator", "description": "Participants will receive placebo 400 mg daily during the first 4 days, followed by 400 mg weekly during 6 months"}], "intervention": [{"intervention_type": "Drug", "intervention_name": "Hydroxychloroquine", "description": "Hydroxychloroquine with the following dosage:\nday 0: 400 mg (2 tablets)\nday 1: 400 mg (2 tablets)\nday 2: 400 mg (2 tablets)\nday 3: 400 mg (2 tablets)\nweekly: 400 mg (2 tablets) for a period of six months", "arm_group_label": "Pre-exposure prophylaxis of SARS-CoV-2"}, {"intervention_type": "Drug", "intervention_name": "Placebos", "description": "Placebo with the following dosage:\nday 0: 400 mg (2 tablets)\nday 1: 400 mg (2 tablets)\nday 2: 400 mg (2 tablets)\nday 3: 400 mg (2 tablets)\nweekly: 400 mg (2 tablets) for a period of six months", "arm_group_label": "Control group with placebo"}], "eligibility": {"criteria": {"textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18 years\n\n          -  Negative PCR and negative serology at day 0\n\n          -  Healthcare worker at Hospital Cl\u00ednic de Barcelona\n\n          -  Female participants: negative for pregnancy test\n\n          -  Willing to participate in the study\n\n          -  Able to sign the informed consent form\n\n        Exclusion Criteria:\n\n          -  Age <18 years\n\n          -  Pregnancy or breastfeeding\n\n          -  Ongoing antiviral or antiretroviral treatment or HIV positive\n\n          -  Ongoing anti-inflammatory treatment (NSAID, corticosteroids)\n\n          -  Ongoing chloroquine or hydroxychloroquine treatment\n\n          -  Confirmed case of SARS-CoV-2 infection (positive PCR) at day 0\n\n          -  Positive serology for SARS-CoV-1 infection at day 0\n\n          -  Impossibility of signing the informed consent form\n\n          -  Rejection of participation\n\n          -  Working less than 5 days a week in the Hospital Clinic of Barcelona.\n\n          -  Any contraindication for hydroxychloroquine treatment:\n\n               -  Hydroxychloroquine hypersensitivity or 4-aminoquinoline hypersensitivity\n\n               -  Retinopathy, visual field or visual acuity disturbances\n\n               -  QT prolongation, bradycardia (<50bpm), ventricular tachycardia, other\n                  arrhythmias, as determined on day 0 ECG or medical history\n\n               -  Potassium < 3 mEq/L or AST or ALT > 5 upper normal limit, as determined on day 0\n                  blood test\n\n               -  Previous myocardial infarction\n\n               -  Myasthenia gravis\n\n               -  Psoriasis or porphyria\n\n               -  Glomerular clearance < 10ml/min\n\n               -  Previous history of severe hypoglycaemia\n\n               -  Ongoing treatment with: antimalarials, antiarrhythmic, tricyclic antidepressants,\n                  natalizumab, quinolones, macrolides, agalsidase alfa and beta."}, "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "Accepts Healthy Volunteers"}, "overall_official": {"last_name": "Jose Mu\u00f1oz Guti\u00e9rrez, MD, PhD", "role": "Principal Investigator", "affiliation": "Barcelona Institute for Global Health"}, "location": {"facility": {"name": "ISGlobal", "address": {"city": "Barcelona", "zip": "08036", "country": "Spain"}}}, "location_countries": {"country": "Spain"}, "verification_date": "April 2020", "study_first_submitted": "April 1, 2020", "study_first_submitted_qc": "April 1, 2020", "study_first_posted": {"@type": "Actual", "#text": "April 2, 2020"}, "last_update_submitted": "April 1, 2020", "last_update_submitted_qc": "April 1, 2020", "last_update_posted": {"@type": "Actual", "#text": "April 2, 2020"}, "responsible_party": {"responsible_party_type": "Sponsor"}, "keyword": "PrEP", "intervention_browse": {"mesh_term": "Hydroxychloroquine"}, "patient_data": {"sharing_ipd": "No"}}}